A B S T R A C T Polydipsia, polyuria, polyphagia, and glucosuria followed the administration of streptozotocin to 6 nonpregnant and 15 pregnant monkeys (Macaca mulatto) in the first trimester of pregnancy. The diabetogenic action of the drug was also reflected in an induced but variable deterioration in maternal intravenous glucose tolerance and a marked attenuation of maternal plasma insulin responsiveness to intravenous glycemic stimuli. The products of conception were examined in 29 pregnancies. The neonates and the placentas of the streptozotocin-treated pregnant animals were significantly heavier than average for the period of gestation, polyhydramnios was consistently present, and there was an increase in the incidence of third trimester stillbirths.
ceptii from the streptozotocin-treated pregnancies was associated with an elevation in fetal and neonatal plasma insulin levels, whereas normal monkey fetuses and neonates required a 10-fold greater concentration of amino acids in the infusate for similar responses. The induced hyperaminoacidemia or hyperglycemia did not consistently alter plasma growth hormone concentrations in the conceptii from normal or streptozotocin-treated pregnancies.
These data provide evidence that maternal glucose intolerance during pregnancy is associated with enhanced fetal and neonatal pancreatic islet cell responsiveness to glucose and mixed amino acids. Although the specific INTRODUCTION Maternal, fetal, and neonatal carbohydrate insulin and growth hormone metabolism in normal monkeys (Macaca mulatto) during the third trimester of pregnancy were detailed in previous studies from our laboratory (1) (2) (3) . During the last trimester fetal plasma insulin concentrations were not altered by exogenously induced acute fetal hyperglycemia. These observations obtained from normal pregnancies provide a basis for comparing fetal and neonatal beta islet cell function in pregnancies complicated by maternal hyperglycemia.
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The hypothesis, primarily advanced by Pedersen, Bojsen-Moller, and Poulsen (4) , is that maternal hyperglycemia is associated with enhanced fetal and neonatal pancreatic islet cell function. Although considerable indirect evidence can be marshalled to support this concept (5) (6) (7) (8) (9) (10) , one of the problems in substantiating directly the validity of the Pedersen hypothesis, has been the absence of an experimental primate model in which to examine antenatal responses. Recently, a pancreatic beta cell cytotoxic agent, streptozotocin, has become available for experimental use in primates (11) and other species (12) (13) (14) . The experiments reported in this paper provide data related to the effects of streptozotocin-induced alteration in maternal metabolism on fetal and neonatal carbohydrate-insulin metabolism and growth and development. (1) (2) (3) . Briefly, under phencyclidine and halothane anesthesia, abdominal laparotomy was performed. After an incision through the myometrium, decidua, and chorion, an interplacental fetal artery or vein was isolated and then cannulated with a silicone rubber T-tube. This T-tube permits both continuous flow through the vessel and sequential sampling of fetal blood while the fetus remains in the intact amniotic sac. Maternal blood was sampled through a cannula placed into the inferior vena cava from insertion at a saphenous vein. Maternal blood samples were approximately 3.0 ml in volume; fetal blood samples did not exceed 1.2 ml. These portions of blood were replaced with equal volumes of dilute heparin-normal saline (5 U/ml).
METHODS
At the end of the intrauterine experiment, the amniotic fluid volume was measured and the fetus delivered and weighed. These newborns and those spontaneously delivered vaginally were transferred to a temperature-controlled, humidified, oxygenated environment. Studies were performed, via the cannulated umbilical vein, on fasted nonanesthetized neonates within 8 hr of life.
Endocrine stimulation studies. The fetal and simultaneous maternal plasma glucose, immunoreactive insulin, and growth hormone responses to single glucose injections, and combined glucose injections and infusions, were examined. In four experiments, glucose injection alone (2 ml of 12.5% glucose in Ringer's lactate) or followed by a glucose infusion (20 mg/0.1 ml per min for 15 min or 50 mg/0.25 ml per min for 10 min) was administered intravascularly directly to the fetus. In three experiments, 250 mg glucose was injected intravenously into the cannulated umbilical vein of the newborn. Blood, samples were withdrawn simultaneously from the fetal and maternal or neonatal circulations before, and 2, 5, 10, 20, 40, and 60 min after the initial injection. In two additional experiments, glucose (0.5 g/kg body weight) was injected intravenously to the mother, and fetal and maternal blood samples were obtained simultaneously before, and 5, 10, 15, 20, and 30 min after the glucose injection.
An infusion of a mixture of nine amino acids (arginine, lysine, phenylalanine, leucine, methionine, valine, histidine, isoleucine, and threonine) (15) at rates of either 2 mg/0.1 ml per min or 20 mg/0.2 ml per min for 30 min was intravenously administered to six fetuses and neonates from streptozotocin-treated and seven conceptii of normal control mothers. Blood samples were obtained from the cannulated interplacental vessels or the umbilical vein before, and 15, 30, 45, and 60 min after the start of the infusion.
The plasma was separated immediately and analyzed in duplicate for glucose by a glucose oxidase method (Glucostat, Worthington Biochemical Corp., Freehold, N. J.). Fetal and maternal plasma insulin and fetal growth hormone concentrations were measured by a modification (16) of the charcoal-coated radioimmunoassay method of Herbert, Kam-Seng, Gottlieb, and Bleicher (17) . The specificity, sensitivity, and reproductivity of the insulin and growth hormone assays were previously reported (1, 2, 18 maternal weight change, obtained by subtracting the and maximum increment from base line plasma insulin placental and fetal weights and amniotic fluid volume concentrations observed during intravenous glucose tolfrom the gross maternal weight changes in the strepto-erance tests. Data obtained at gestational age 55-65 days zotocin-treated animals was greater than that in the before streptozotocin administration and then at three normal pregnancies (P <0.01). However, in 38% of subsequent tests at monthly intervals until delivery are the streptozotocin-treated group it was not possible to presented. In the six animals which received streptozoobtain this determination because of vaginal delivery tocin before conception, the data at gestational age with loss of amniotic fluid, or cannibalization of the 55-65 days were obtained during a previous normal placenta, or both. pregnancy, before the administration of the drug. Table II provides a sequential tabulation of the maThe maternal fasting plasma glucose levels in the conternal fasting plasma glucose and immunoreactive in-trol and the test animals before streptozotocin injection sulin concentrations, and the plasma glucose disappear-were identical Subsequently, the mean fasting plasma ance half times (obtained from a semilog plot of the glucose concentration observed at each monthly inter- (Fig. 1) ; the other fetal weights were in accord with or less than the reported normal range at this time in gestation (20) (21) (22) Fig. 1 . All of the fetal weights and most of the placental weights exceed the stippled rectangles which identify the means ±2 SEM of 473 fetal weights and 131 placental weights recorded from normal gestations reported in the literature (20) (21) (22) (23) (24) . Eight of the treated animals had had a previous normal pregnancy delivered near term before the streptozotocin-treated pregnancy. Five of the control animals also had previously delivered near term. All the fetal and placental weights of the present control and the previous normal pregnancies were within the reported normal ranges.
The mean ±2 SEM of 62 amniotic fluid volumes from the control animals and other normal rhesus monkey pregnancies reported in the literature (20, 22) is 87 ±13 ml at 139-148 days gestation. Amniotic fluid volume was available for measurement in 18 streptozotocintreated pregnancies. The range of these values was 104-458 ml with a mean of 190 ml. This was significantly different from normal (P < 0.01). There was no correlation between maternal oral fluid intake, urinary output, magnitude of glucosuria, or extent of induced glucose intolerance and the measured amniotic fluid volume. Therefore, in the third trimester, statistically signifi- DISCUSSION A diabetes mellitus-like syndrome was consistently obtained after the administration of the pancreatic beta cell cytotoxin, streptozotocin, to rhesus monkeys before conception and during the first trimester of pregnancy. The conceptii of these streptozotocin-treated animals demonstrated changes similar to those encountered in pregnancies of women with diabetes mellitus (25, 26) . Specifically, these simian neonates and placentas were statistically significantly heavier than average for their gestational age, polyhydramnios was consistently encountered, and a well defined increase in the incidence of third trimester stillbirths for this colony was observed. These clinical features were present in both gestations in which normal female rhesus monkeys were treated with streptozotocin before conception or during early gestation. Thus, the evidence is that the maternal metabolic alterations induced by the drug, streptozotocin, and not the immediate pharmacologic effects of drug per se, are responsible for the changes observed in fetal growth and development.
Primate Fetal Islet Cell Responsiveness in Induced Diabetes Mellitus
As a group the streptozotocin-treated females demon- (Table   III) . In contrast, in normal pregnancies fetal plasma insulin levels are not significantly altered from base line despite the induction and maintenance of hyperglycemia (blood glucose> 300 mg/100 ml) for as long as 120 min (1) .
The specific mechanism whereby the normal fetal pancreatic islet cell unresponsiveness to glucose is reversed remains unclear. The Pedersen hypothesis focuses upon the primary and critical role of persistent or intermittent maternal-fetal hyperglycemia in the alteration of the fetal insulin releasing mechanism. However, the data from the individual animals depicted in These conceptii from streptozotocin-treated pregnancies respond with elevations in plasma insulin levels to an infusion of a low concentration (2 mg/mnin) of amino acids whereas monkey fetuses and neonates from normal pregnancies (Table IV) and human premature infants (15) require a 10-fold greater concentration of amino acids in the infusate for a similar response. These observations suggest that in the streptozotocin-treated pregnancies the fetal and neonatal pancreatic islets are more sensitive to the insulinogenic action of amino acids. Moreover, since elevations in the plasma concentrations of the insulinogenic amino acids valine, leucine, and isoleucine, do occur in spontaneous (27) and acquired (28) diabetes, the streptozotocin-induced diabetes-like state could result in an increased availability of these amino acids to the fetal blood pool (29, 30) . Thus, fetal hyperinsulinemia could result from relatively augmented fetal plasma amino acid levels in the absence Primate Fetal Islet Cell Responsiveness in Induced Diabetes Mellitusof fetal hyperglycemia. A similar independent regulation of pancreatic insulin secretion by the plasma amino acids has been postulated in human obesity (31) . Lastly, fetal hyperglycemia and hyperaminoacidemia could also act synergistically as well as independently in enhancing fetal islet cell function (32) . Definitive clarification of the role of hyperglycemia and hyperaminoacidemia, alone or in combination, will require the direct measurement of plasma amino acid in both fetal and maternal blood pools. ' Similar to our observations in the normal control studies (1-3), fetal and neonatal plasma growth hormone concentrations were not consistently altered in the presence of hyperglycemia or hyperaminoacidemia in the streptozotocin-treated pregnancies. Nor were fetalneonatal differences identified in mean plasma growth hormone levels. The average base line growth hormone level in the treated fetuses was 8 ±2.8 ng/ml and the treated neonates, 9 ±2.2 ng/ml. The mean of the fetal base line plasma growth hormone concentration in the streptozotocin-treated pregnancies is less than the base line mean plasma growth hormone levels (16.0 ±1.4 ng/ ml) observed in our normal controls (P < 0.005). The same direction of difference was observed in human cord blood when samples from normal pregnancy were compared to those from pregnancies complicated by diabetes mellitus (33) . However, the disparity in sample size in our study (9 streptozotocin-treated pregnancies vs. 42 control pregnancies) confounds any specific interpretation. Further studies will be necessary to establish whether the fetal growth hormone-releasing mechanism is also altered in the presence of compromised maternal carbohydrate and insulin metabolism.
8 of the 29 gestations in animals treated with streptozotocin were complicated by second or third trimester deadborns. This fetal complication parallels that observed in human gestation complicated by diabetes mellitus when no special care is taken (34, 35) . One of the more enigmatic problems which the present study also highlights is the apparent lack of any correlation between the extent or magnitude of the maternal metabolic alterations and fetal survival. Thus, the mean of the fasting maternal plasma glucose and insulin, the insulin, responses, and plasma glucose disappearance rates to intravenous glucose in the eight pregnancies associated with deadborns were not significantly different from the streptozotocin-treated animals from which liveborn offspring were obtained.
In further emphasis, when human gestation complicated by diabetes mellitus is managed under optimum conditions of therapy and control of the hyperglycemia, a substantial fetal loss rate is still encountered (36, 37 ).
It appears that the fetal loss rate will not be further ameliorated until some decisive increase in our knowledge of the reasons why these babies die is obtained.
The animal model detailed in this paper may provide an experimental opportunity to improve further our understanding of the etiology of this refractory perinatal mortality.
